LOGC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LOGC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. LogicBio Therapeutics's annualized Gross Profit for the quarter that ended in Jun. 2022 was $12.80 Mil. LogicBio Therapeutics's average Total Assets over the quarter that ended in Jun. 2022 was $49.46 Mil. Therefore, LogicBio Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2022 was 25.87%.
The historical data trend for LogicBio Therapeutics's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LogicBio Therapeutics Annual Data | |||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||
Gross-Profit-to-Asset % | Get a 7-Day Free Trial | - | - | - | 5.07 | 7.54 |
LogicBio Therapeutics Quarterly Data | ||||||||||||||||||||
Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | |
Gross-Profit-to-Asset % | Get a 7-Day Free Trial | 4.23 | 11.61 | 12.38 | 19.65 | 25.87 |
For the Biotechnology subindustry, LogicBio Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, LogicBio Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where LogicBio Therapeutics's Gross-Profit-to-Asset % falls into.
LogicBio Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2021 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (A: Dec. 2021 ) | / | ( (Total Assets (A: Dec. 2020 ) | + | Total Assets (A: Dec. 2021 )) | / count ) |
= | 5.41 | / | ( (80.64 | + | 62.77) | / 2 ) | |
= | 5.41 | / | 71.705 | ||||
= | 7.54 % |
LogicBio Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2022 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (Q: Jun. 2022 ) | / | ( (Total Assets (Q: Mar. 2022 ) | + | Total Assets (Q: Jun. 2022 )) | / count ) |
= | 12.796 | / | ( (51.899 | + | 47.017) | / 2 ) | |
= | 12.796 | / | 49.458 | ||||
= | 25.87 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Thank you for viewing the detailed overview of LogicBio Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark J Enyedy | director | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Mariana Nacht | officer: Chief Scientific Officer | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Daniel Gruskin | officer: Chief Medical Officer | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Susan Kahn | director | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Joshua Blacher | officer: Interim CFO | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Andrea Paul | officer: General Counsel and Secretary | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Frederic Chereau | director, officer: See Remarks | C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Kyle Chiang | officer: Chief Operating Officer | 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Cecilia Jones | officer: Chief Financial Officer | C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Jonathan Quick | officer: Senior Director-Finance | C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421 |
Jeff Goater | director | C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139 |
Daphne Karydas | director | 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451 |
Erez Chimovits | director | P.O. BOX 4023, HERZLIYA PITUACH L3 4614001 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By PRNewswire PRNewswire • 06-05-2022
By PRNewswire PRNewswire • 05-19-2022
By PRNewswire PRNewswire • 05-29-2022
By PRNewswire PRNewswire • 06-25-2022
By PRNewswire PRNewswire • 05-21-2022
By PRNewswire PRNewswire • 07-06-2022
By Value_Insider Value_Insider • 10-15-2022
By PRNewswire PRNewswire • 11-14-2022
By PRNewswire PRNewswire • 07-05-2022
By PRNewswire PRNewswire • 06-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.